We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+14.9%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$272M
AUM Growth
+$12.6M
Cap. Flow
-$13.6M
Cap. Flow %
-4.98%
Top 10 Hldgs %
27.33%
Holding
177
New
29
Increased
50
Reduced
55
Closed
31

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$4.13M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$2.18M
3
CLDX icon
Celldex Therapeutics
CLDX
+$2.07M
4
CLF icon
Cleveland-Cliffs
CLF
+$1.9M
5
FERG icon
Ferguson
FERG
+$1.82M

Top Sells

Rank Stock Value
1
ACI icon
Albertsons Companies
ACI
+$4.15M
2
SWTX
SpringWorks Therapeutics
SWTX
+$3.03M
3
GEV icon
GE Vernova
GEV
+$2.41M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$2.1M
5
BHC icon
Bausch Health
BHC
+$2.03M

Sector Composition

Rank Sector Weight
1 Healthcare 37.62%
2 Technology 22.09%
3 Industrials 8.52%
4 Financials 6.08%
5 Consumer Discretionary 5.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBC icon
1
Invesco DB Commodity Index Tracking Fund
DBC
$1.67B
$31.3M 11.51%
1,436,136
– –
VRDN icon
2
Viridian Therapeutics
VRDN
$2.18B
$6.77M 2.49%
484,559
+304,008
+168% +$4.13M
ANSS
3
DELISTED
Ansys
ANSS
$6.01M 2.21%
17,100
+4,300
+34% +$1.41M
MSFT icon
4
Microsoft
MSFT
$2.89T
$5.1M 1.88%
10,258
+500
+5% +$217K
MRUS
5
DELISTED
Merus
MRUS
$4.72M 1.74%
89,762
+34,723
+63% +$1.63M
JNPR
6
DELISTED
Juniper Networks
JNPR
$4.58M 1.68%
114,700
– –
AMZN icon
7
Amazon
AMZN
$2.49T
$4.14M 1.52%
18,893
+200
+1% +$39.6K
HES
8
DELISTED
Hess
HES
$4M 1.47%
28,900
– –
AMED
9
DELISTED
Amedisys
AMED
$3.86M 1.42%
39,250
– –
NUVL
10
DELISTED
Nuvalent
NUVL
$3.85M 1.41%
50,460
+10,584
+27% +$774K
AVGO icon
11
Broadcom
AVGO
$1.82T
$3.53M 1.3%
12,800
-3,100
-19% -$673K
WDC icon
12
Western Digital
WDC
$172B
$3.24M 1.19%
50,600
+2,300
+5% +$110K
AKRO
13
DELISTED
Akero Therapeutics
AKRO
$3.2M 1.18%
59,993
+35,926
+149% +$1.63M
PTGX icon
14
Protagonist Therapeutics
PTGX
$8.72B
$3.2M 1.18%
57,851
-20,601
-26% -$989K
STX icon
15
Seagate
STX
$185B
$3.19M 1.17%
22,100
-900
-4% -$93.2K
CORZ icon
16
Core Scientific
CORZ
$6.59B
$3.07M 1.13%
179,900
-19,200
-10% -$192K
CRM icon
17
Salesforce
CRM
$142B
$3.05M 1.12%
11,185
+1,900
+20% +$508K
IMVT icon
18
Immunovant
IMVT
$8.23B
$2.92M 1.07%
182,808
+87,160
+91% +$1.32M
BBIO icon
19
BridgeBio Pharma
BBIO
$16.5B
$2.91M 1.07%
67,499
+20,999
+45% +$764K
XOMA
20
DELISTED
Xoma
XOMA
$2.89M 1.06%
114,548
– –
ELVN icon
21
Enliven Therapeutics
ELVN
$3.77B
$2.84M 1.04%
141,516
+29,057
+26% +$550K
PRAX icon
22
Praxis Precision Medicines
PRAX
$8.8B
$2.83M 1.04%
67,288
+28,002
+71% +$1.07M
VRNA
23
DELISTED
Verona Pharma
VRNA
$2.73M 1%
28,880
+12,179
+73% +$902K
CEG icon
24
Constellation Energy
CEG
$96.4B
$2.68M 0.98%
8,300
-1,800
-18% -$476K
XPO icon
25
XPO
XPO
$24.4B
$2.66M 0.98%
21,080
-5,800
-22% -$651K
1
2 3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return

HighVista Strategies's Q2 2025 Portfolio in Review

As of Q2 2025, HighVista Strategies held 177 positions worth $272M, up 4.9% from $260M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HighVista Strategies withdrew a net $13.6M in Q2 2025, closing 31 positions and reducing 55 holdings. Its most notable exit was Albertsons Companies, an estimated $4.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Mineralys Therapeutics worth $2.03M.

  • HighVista Strategies's largest Q2 2025 buy was Mineralys Therapeutics: 150,138 shares worth $2.03M.
  • HighVista Strategies added most to Viridian Therapeutics in Q2 2025, an estimated $4.13M increase.
  • HighVista Strategies's biggest Q2 2025 reduction was GE Vernova, cutting an estimated $2.41M.
  • HighVista Strategies fully exited Albertsons Companies in Q2 2025, selling an estimated $4.15M.
  • HighVista Strategies's ten largest holdings make up 27% of its $272M portfolio in Q2 2025.
  • HighVista Strategies opened 29 new positions and closed 31 in Q2 2025.
  • HighVista Strategies's portfolio value rose 4.9% quarter-over-quarter to $272M.

Based on HighVista Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.